New cytotoxic agents: a review of the literature

This publication has 100 references indexed in Scilit:

• A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer
  Lung Cancer, 2004
• RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group
  European Journal of Cancer, 2004
• Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
  Blood, 2003
• Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five Days
  Journal of Clinical Oncology, 2003
• Phase I Study of Prolonged Infusion Bryostatin-1 in Patients
  Cancer Biology & Therapy, 2002
• Bendamustin, Vincristin, Prednisolon (BOP) in der Therapie von fortgeschrittenen niedrig malignen Non-Hodgkin-Lymphomen
  DMW - Deutsche Medizinische Wochenschrift, 2001
• Bendamustine
  Drugs, 2001
• Treatment of patients with metastatic melanoma with bryostatin-1 - phase II study
  Melanoma Research, 1999
• Antitumor Activity of TZT‐1027, a Novel Doiastatin 10 Derivative
  Japanese Journal of Cancer Research, 1997
• A New Water‐soluble Camptothecin Derivative, DX‐8951f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivo
  Japanese Journal of Cancer Research, 1995